

Pathologisches Institut  
Prof. Dr. med. Arne Burkhardt  
Obere Wässere 3-7  
72764 Reutlingen

BioNTech SE  
z.H. Prof. Dr. Ugur Sahin  
An der Goldgrube 12  
55131 Mainz  
via Email: service@biontech.de

Reutlingen, February 3, 2022

### **Inquiry about the vaccine Cormirnaty®**

Dear Professor Sahin,  
Dear Sir or Madam,

The pathological examinations carried out by the undersigned raise the fundamental question of the extent to which massive damage to organs, which led to deaths, could be causally or contributory related to the vaccine Cormirnaty® or, alternatively, whether this relationship can be excluded with probability bordering on certainty on the basis of scientific findings.

In this context, we would like to ask you to answer the following questions:

1.  
In which cells of which organs or tissues should spike proteins after intramuscular Cormirnaty® injection trigger the formation of spike proteins and the immune response?
2. Can it be excluded that the spike proteins are formed outside the cells you indicated in point 1? If yes, on the basis of what scientifically validated data can this be excluded?
3. How long does the coding ability of the mRNA persist in the body of the vaccinated person? In this regard, can it be excluded that it persists for weeks/months?
4. After what time for the latest should the mRNA from the lipid nanoparticles have degraded in the body of the vaccinated person?
5. Is it ensured that the spike protein formed in the transfected cells of the vaccinated person is exclusively incorporated into the membranes of the affected cells ("remains at the vaccination site") and does not circulate solubly in the body?
6. What is done to ensure that the lipid nanoparticles remain at the advertised nanosize and do not potentially fuse in the body (and body vessels) to form larger lipid droplets?
7. What is the half-life of the lipid nanoparticle components in the body? How quickly are they broken down and metabolized or excreted?
8. How many lipid nanoparticles are contained in a dose of Cormirnaty® and what is the order of magnitude of variation between the individual doses?

9. How many mRNA sequences are contained in one LNP and what is the range of variation?

10. In which form according to your homepage four mRNA formats is the mRNA present in Cormirnaty©?

We assume that on the basis of the scientific data available to you, a short-term answer is possible. We have therefore noted a resubmission deadline of 02/09/2022.

We look forward to your reply and remain yours faithfully,

Professor Dr. Arne Burkhardt

Professor Dr. Wolfgang Lang